Cambrian Bio
PrivateLast Round
Undisclosed
Dec 22, 2023
Est. Valuation
$497M
Total Funding Raised
$216.5M
Company Overview
Cambrian Bio operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was an Undisclosed round in December 2023.
Cambrian Bio is a biotechnology and venture capital company that builds, finances, and manages a portfolio of companies developing therapeutics for age-related diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Biotech Equipment
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cambrian Bio Comparables
Compare Cambrian Bio with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Juvenescence | 84% | |
| BioAge Labs | 79% | |
| Centenara Labs AG | 79% |
For institutional investors. Book with your work email.
Cambrian Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Undisclosed | Dec 22, 2023 | ||||
| Series C | Oct 26, 2021 | ||||
| VC Round | Feb 9, 2021 | ||||
| Early Funding | Jan 17, 2020 | ||||
| Series A | Nov 22, 2019 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Cambrian Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Future Ventures | Series C, Early Funding, VC Round |
| Galaxy Digital | VC Round, Early Funding |
| SALT | Series C |
| Lux Capital | Series C |
| Catalio Capital Management | Early Funding, VC Round |
| Apeiron Investment Group | Series C, Early Funding, VC Round |
| Infinitas Capital | Series C |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 25, 2026
TOR-101 asset is in IND-enabling development for clinical studies.
- Mar 25, 2026
ATX-304 is advancing through clinical trials for obesity treatment.
For institutional investors. Book with your work email.
Cambrian Bio Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Cambrian Bio's valuation, stock price, and market status.
Is Cambrian Bio a public or private company?
Cambrian Bio is a private company.
What is the current stock price of Cambrian Bio?
Cambrian Bio is a private company, so its shares have no public market price. Caplight tracks Cambrian Bio's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Cambrian Bio worth (valuation)?
Cambrian Bio's valuation is estimated at $497.0M based on funding round data.
Can I buy Cambrian Bio stock?
Cambrian Bio shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Cambrian Bio's last funding round?
Cambrian Bio's most recent funding round was Undisclosed on December 22, 2023.
Who are the main investors in Cambrian Bio?
Key investors in Cambrian Bio include Future Ventures, SALT, Catalio Capital Management, Apeiron Investment Group, Anthos Capital.
Will Cambrian Bio IPO soon?
No public IPO plans have been announced for Cambrian Bio.
How can I track Cambrian Bio secondary market activity?
Caplight tracks bids, offers, and trades in Cambrian Bio's shares on secondary markets.